DRMA net incomeQ2 2026-$2.97M
DRMA net income was -$2.97M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.70M a year earlier. For the full fiscal 2025 it was -$7.56M, compared with -$12.29M in fiscal 2024.
Dermata Therapeutics Inc. (DRMA) financials
For the twelve months ended Jun 30, 2026, Dermata Therapeutics Inc. reported -$8.37M of net income.
- Net income, TTM
- -$8.37M
- Cash
- $4.41M
- Market cap
- $3.8M
FY2020FY2025
DRMA revenue and earnings growth
DRMA EPSQ2 2026-$0.74
DRMA diluted EPS was -$0.74 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$8.16.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $2.93M | $8.20M | $4.07M | $5.65M | $3.46M | $1.61M |
| Selling, general and admin | $4.84M | $4.31M | $3.97M | $4.02M | $4.40M | $1.57M |
| Operating income | -$7.77M | -$12.51M | -$8.04M | -$9.67M | -$7.86M | -$3.17M |
| Interest expense | - | - | - | - | $45.6K | $197.3K |
| Income tax | - | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | -$7.90M | -$3.24M |
| EPS, basic | -$8.16 | -$80.32 | -$39.99 | -$13.92 | -$2.43 | -$1.69 |
| EPS, diluted | -$8.16 | -$80.32 | -$39.99 | - | - | - |
| Diluted shares | 926,192 | 152,974 | 194,928 | - | - | - |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $7.52M | $3.16M | $7.44M | $6.24M | $10.80M | $530.4K |
| Current assets | $7.86M | - | - | - | $11.62M | $605.5K |
| Total assets | $7.86M | $3.53M | $7.98M | $6.94M | $11.62M | $605.5K |
| Current liabilities | - | - | - | - | $1.52M | $3.78M |
| Short-term debt | - | - | - | - | $0 | $556.2K |
| Long-term debt | - | - | - | - | $0 | $1.14M |
| Total debt | - | - | - | - | $0 | $1.70M |
| Total liabilities | $1.64M | $1.97M | $1.62M | $922.6K | $1.52M | $3.78M |
| Shareholders' equity | $6.22M | $1.56M | $6.36M | $6.02M | $10.11M | -$3.18M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.76M | -$11.16M | -$6.41M | -$8.83M | -$5.69M | -$4.03M |
| Financing cash flow | $12.12M | $6.89M | $7.61M | $4.28M | $15.96M | $2.57M |
| Stock-based compensation | $143.7K | $657.6K | $522.1K | $930.3K | $1.91M | $0 |
| Depreciation and amortization | - | - | - | - | $0 | $322 |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $212.6K | $383.7K | $526.6K | $504.4K | $617.8K | $1.28M | $2.19M | $2.40M | $2.01M | $1.60M | $1.14M | $903.0K |
| Selling, general and admin | $2.80M | $1.54M | $1.37M | $1.26M | $1.15M | $1.06M | $1.01M | $824.3K | $874.6K | $1.60M | $1.08M | $909.0K |
| Operating income | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | -$2.34M | -$3.20M | -$3.23M | -$2.88M | -$3.20M | -$2.22M | -$1.81M |
| Net income | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | -$2.30M | -$3.15M | -$3.17M | -$2.83M | -$3.13M | -$2.13M | -$1.72M |
| EPS, basic | -$0.74 | -$0.48 | - | -$1.65 | -$1.22 | -$4.47 | - | -$20.41 | -$41.82 | -$7.06 | - | -$0.54 |
| EPS, diluted | -$0.74 | -$0.48 | - | -$1.65 | -$1.66 | -$4.47 | - | -$20.41 | -$41.82 | -$7.06 | - | - |
| Diluted shares | 4.0M | 3.9M | - | 1.0M | 1.0M | 515,465 | - | 155,465 | 67,654 | 443,998 | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | $9.72M | $3.16M | $6.14M | $4.95M | $4.73M | $7.44M | $6.63M |
| Inventory | $149.7K | $93.1K | - | - | - | - | - | - | - | - | - | - |
| Current assets | $5.16M | - | $7.86M | - | - | - | - | - | - | - | - | - |
| Total assets | $5.32M | $7.47M | $7.86M | $5.07M | $6.64M | $10.01M | $3.53M | $6.69M | $5.24M | $5.18M | $7.98M | $7.32M |
| Total liabilities | $1.83M | $1.05M | $1.64M | $1.11M | $1.03M | $2.70M | $1.97M | $1.95M | $1.92M | $1.37M | $1.62M | $916.8K |
| Shareholders' equity | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | $7.30M | $1.56M | $4.74M | $3.32M | $3.81M | $6.36M | $6.41M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.42M | -$2.48M | -$1.33M | -$1.80M | -$2.69M | -$1.93M | -$2.91M | -$3.42M | -$2.13M | -$2.70M | -$1.15M | -$1.77M |
| Financing cash flow | -$323 | $1.90M | $4.19M | -$13.0K | -$547.9K | $8.49M | -$68.6K | $4.62M | $2.34M | $0 | $1.95M | -$35.4K |
| Stock-based compensation | $41.8K | $43.3K | $29.5K | $37.8K | $39.2K | $37.2K | $29.8K | $21.0K | $19.6K | $587.2K | $128.5K | $131.2K |
Key ratios
Source: XBRL data Dermata Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DRMA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DRMA | - | - | -$8.37M | - | $3.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
DRMA FAQ
4 questionsIs DRMA profitable?
No. Dermata Therapeutics Inc. reported a net loss of $8.37M for the twelve months ended Jun 30, 2026.How much cash and debt does DRMA have?
Dermata Therapeutics Inc. reported $4.41M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did DRMA last report financial results?
The latest statements here come from Dermata Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this DRMA financial data come from?
Quantisnow builds these statements from the structured XBRL data Dermata Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.